A recent study investigating the molecular mechanisms of tamoxifen resistance in BC confirmed these findings and described lower ELOVL2 expression in tamoxifen-resistant models and ELOVL2 downregulation in patients with tamoxifen resistance [135]. The gene discussed is ELOVL2; the disease is breast cancer.